Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals
Decision in the Arzerra Patent Infringement Case

Company Announcement

  oGenentech and Biogen Idec have filed for re-hearing in the United States

COPENHAGEN, Denmark, May 17, 2013 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today that Genentech and Biogen Idec have filed for
a re-hearing en banc (i.e. before all judges of the court) in the appeal case,
where the U.S. Court of Appeals for the Federal Circuit recently upheld the
U.S. District Court's judgment in favor of GlaxoSmithKline (GSK). The appeal
case relates to a patent infringement case involving Arzerra^® brought against
GSK by Genentech and Biogen Idec.

Genentech and Biogen Idec claim that the decision from the US court of appeals
announced on April 16, 2013 in favor of GSK was against court precedent and
request the US court of appeals to reconsider the case. The court of appeals
will now decide whether to grant the rehearing.

Genentech and Biogen Idec originally filed the lawsuit in 2010 in the U.S.
District Court for the Southern District of California claiming that Arzerra
infringed U.S. Patent No. 7,682,612 covering methods of treating Chronic
Lymphocytic Leukemia (CLL) with CD20 antibodies. GSK denied infringement and
claimed the patent was invalid and unenforceable. An initial judgement by the
court in favor of GSK in December 2011 was subsequently appealed by Genentech
and Biogen Idec. In April 2013 the US court of appeals upheld the original
decision by the US district court in favor of GSK.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer.Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra^®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development.Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates.Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies.For more information
visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^®; the
Y-shaped Genmab logo^®; the DuoBody™ logo; HuMax^®; HuMax-CD20^®; DuoBody^®,
HexaBody^TM and UniBody^®. Arzerra^® is a trademark of GlaxoSmithKline.

Company Announcement no. 23
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Attachments:

23 arzerra patent infringement case_uk_170513.pdf